Showing 4161-4170 of 10206 results for "".
- FDA Approves PMA Supplement for MelaFind from STRATA Scienceshttps://practicaldermatology.com/news/fda-accepts-pma-for-melafind-from-strata-sciences/2458644/The FDA has approved STRATA Skin Sciences, Inc.’s PMA supplement for the MelaFind System. The FDA approved MelaFind’s use of the “classifier score data”, a quantitative result derived by the MelaFind System that can be beneficially used in conjunction with the previously a
- U.S. Cosmetics Survey: The Millennials Lead the Packhttps://practicaldermatology.com/news/us-cosmetics-survey-the-millennials-lead-the-pack/2458733/Once again, it’s all about the millennials! Fresh off the heels of the American Academy of Facial Plastic and Reconstructive Surgery’s annual survey that showed an uptick in the number of millennials seeking nips and tucks, new research finds that millennial women are the heav
- Modernizing Medicine Introduces Practice Management Solutionhttps://practicaldermatology.com/news/modernizing-medicine-introduces-practice-management-solution/2458792/Modernizing Medicine, Inc., creator of the Electronic Medical Assistant® (EMA™), introduced its new practice management solution, modmed PM, at the company’s second annual EMA Nation Users Conference. Building on the success Modernizing Medicine has achieved by employing s
- Dermatologist Harold Lancer and Ryan Seacrest Collaborate on Male Skincare Linehttps://practicaldermatology.com/news/dermatologist-harold-lancer-and-ryan-seacrest-collaborate-on-male-skincare-line/2458814/Dr. Harold Lancer and radio personality, television host and producer Ryan Seacrest have revealed an exclusive partnership in the burgeoning men's grooming category. They plan to launch a men's skincare line late in 2016. This pairing combines Dr. Lan
- MELA Sciences Announces Election of R. Rox Anderson, MD, to Board of Directorshttps://practicaldermatology.com/news/mela-sciences-announces-election-of-r-rox-anderson-md-to-board-of-directors/2458845/R. Rox Anderson, M.D., was elected to the MELA Sciences, Inc.’s board of directors at its Annual General Meeting of Stockholders held on September 30, 2015 in Philadelphia. With Dr. Anderson's election, the MELA board of directors has increased to seven members, six of whom are independ
- Simulated Patient Encounter Part of Summer AAD Programhttps://practicaldermatology.com/news/simulated-patient-encounter-part-of-summer-aad-program/2458888/Simulated patient encounters have come to the American Academy of Dermatology's summer meeting, offering a unique, hands-on educational experience for attendees. Speaking to Seemal Desai, MD for DermTube.com's coverage of the 2015 Summer Meeting of the AAD in New York City, Kanade Shinkai
- Murad Partners with AAD to Launch Shade America Programhttps://practicaldermatology.com/news/murad-partners-with-aad-to-launch-shade-america-program/2458951/Murad, Inc. partnered with the American Academy of Dermatology (AAD) to launch Shade America, a new program that will build shade structures in parks and playgrounds across America to provide shade from the sun’s harmful rays. Through the Shade America program, Murad’s goal is to prov
- Dr. Reddy's and its Subsidiary Promius Pharma File Three NDAshttps://practicaldermatology.com/news/dr-reddys-and-its-subsidiary-promius-pharma-announce-filing-of-three-ndas/2458971/Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC filed three 505(b)(2) New Drug Applications (NDAs) with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in
- Encouraging Preclinical Results Seen for Scinai’s NanoAbs in Plaque Psoriasishttps://practicaldermatology.com/news/encouraging-preclinical-results-seen-for-scinais-nanoabs-in-plaque-psoriasis/2462006/Scinai Immunotherapeutics Ltd.’s anti‑interleukin 17 (IL‑17) NanoAbs downregulated key molecular markers that are overexpressed in plaque psoriasis, according to preclinical data relased by Scinai. Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-
- FDA Clears Sofwave’s SUPERB Technology for Treating Acne Scarshttps://practicaldermatology.com/news/fda-clears-sofwaves-superb-technology-for-treating-acne-scars/2461969/The U.S. Food and Drug Administration (FDA) has cleared Sofwave’s SUPERB technology for treating acne scars. “Gaining FDA clearance to market SUPERB for the treatment of acne scarring not only paves the way to positively impact patients seeking improved appearances